Minerva Neurosciences, Inc.
21.3.2017 21:12 | Nasdaq OMX
Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
WALTHAM, Mass., 2017-03-21 21:10 CET (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, today announced the recent exercise of warrants held by certain institutional stockholders in connection with a private placement that took place in March 2015, as well as a purchase of common stock completed on the open market by the chairman of Minerva’s board of directors.
Since December 31, 2016, warrants with respect to a total of 1,621,073 shares have been exercised by such stockholders at an exercise price of $5.772 per share. As a result, the Company has received approximately $9.4 million in proceeds since December 31, 2016. The warrants issued in connection with the private placement expired on March 20, 2017.
Separately, 50,000 shares of Minerva common stock have been purchased by Marc Beer, chairman of the board of directors of Minerva. These purchases took place in multiple transactions at prices ranging from $7.65 to $8.45 and have been reflected in a Form 4 filing with the Securities and Exchange Commission on March 21, 2017.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visitwww.minervaneurosciences.com.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Safway Group16.8.2017 19:41 | pressemeddelelse
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV
Abeona Therapeutics Inc16.8.2017 15:39 | pressemeddelelse
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
Callidus Software16.8.2017 14:02 | pressemeddelelse
CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards
Ascom Holding AG16.8.2017 08:02 | pressemeddelelse
Ascom Myco and Koutio Médipôle optimize care communications and responsiveness
VistaJet Ltd15.8.2017 18:42 | pressemeddelelse
VistaJet Harnesses the Power of the American Eclipse to Offer Customers a Rare Viewing Opportunity
NGX Bio15.8.2017 17:01 | pressemeddelelse
NGX Bio Raises $3 Million to Fund Growth of Its DNA Sequencing Marketplace
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum